Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
01. März 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
14. Februar 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
08. Februar 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
08. Dezember 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
10. November 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
03. November 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30%...
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
27. Oktober 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
09. August 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second...
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
02. August 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...